Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study

British Journal of Dermatology

Volumn 148, Issue 6, 2003, Pages 1212-1221

  Kawashima, Makoto ^a   Tango, T ^b   Noguchi, T ^c   Inagi, M ^c   Nakagawa, H ^d   Harada, S ^e  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^c Aventis Pharma Ltd   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e Kanto Teishin Hospital   (Japan)

Author keywords

Antihistamine; Atopic dermatitis; Fexofenadine; Histamine; Pruritus

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CORTICOSTEROID; FEXOFENADINE; HYDROCORTISONE BUTYRATE; PROTEIN;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ATOPIC DERMATITIS; BILIRUBIN BLOOD LEVEL; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; KIDNEY DISEASE; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PRURITUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE;

ADOLESCENT; ADULT; AGED; ANTI-ALLERGIC AGENTS; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PRURITUS; TERFENADINE; TREATMENT OUTCOME;

EID: 0038346446     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2003.05293.x     Document Type: Article

References (30)

1. Wüthrich B. Clinical aspects, epidemiology. and prognosis of atopic dermatitis. Ann Allergy Asthma Immunol 1999; 83: 464-70.
2. Sampson HA. Pathogenesis of eczema. Clin Exp Allergy 1990; 20: 459-67.
3. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISSAC. Lancet 1998; 351: 1225-32.
4. Sugiura H, Umemoto N, Deguchi H et al. Prevalence of childhood and adolescent atopic dermatitis in a Japanese population: comparison with the disease frequency examined 20 years ago. Acta Derm Venereol 1998; 78: 293-4.
5. Correale CE, Walker C, Murphy L, Craig TJ. Atopic dermatitis: a review of diagnosis and treatment. Am Fam Physician 1999; 60: 1191-8, 1209-10.
6. Wahlgren CF, Itch and atopic dermatitis. J Dermatol 1999; 26: 770-9.
7. Lundberg L, Johannesson M, Silverdahl M et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999; 141: 1067-75.
8. Finlay AY. Measures of the effect of adult severe atopic eczema on quality of life. J Eur Acad Dermatol Venereol 1996; 7: 149-54.
9. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4: 1-191.
10. Klein PA, Clark RAF. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999; 135: 1522-5.
11. Paul E, Berth-Jones J, Ortonne J-P, Stern M. Fexofenadine hydrochloride in the treatment of chronic idiopathic urticaria: a placebo-controlled, parallel-group, dose-ranging study. J Dermatol Treat 1998; 9: 143-9.
12. Finn AF Jr, Kaplan AP, Fretwell R et al. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999; 104: 1071-8.
13. Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria, Ann Allergy Asthma Immunol 2000; 84: 517-22,
14. van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120mg, loratadine 10mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000; 30: 891-9.
15. Casale TB, Andrade C, Qu R. Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc 1999; 20: 193-8.
16. Howarth PH, Stern MA, Roi L et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 927-33.
17. Abdelaziz MM, Devalia JL, Khair OA et al. Effect of fexofenadine on eosinophil induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1998; 101: 410-20.
18. Paolieri F, Battifora M, Riccio AM et al. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. Ann Allergy Asthma Immunol 1998; 81: 601-7.
19. Vena GA, Cassano N, Filotico R et al. Effect of fexofenadine on adhesion molecules and mast cell proteases in chronic idiopathic urticaria. Allergy 2000; 55 (Suppl. 63); 12 (Abstr.).
20. Marone G, Gentile M, Patraroli A et al. Histamine-induced activation of human lung macrophages. Int Arch Allergy Immunol 2001; 124: 249-52.
21. Amon U, Amon S, Gibbs BF. In vitro studies with fexofenadine, a new nonsedating antihistamine H1 receptor antagonist, on isolated human basophils. Inflamm Res 2000; 49 (Suppl. 1): S13-14.
22. Wittmann M, Kienlin P. Downregulation of co-stimulatory molecules on lymphocytes and decreased lymphocyte proliferation by fexofenadine. Allergy 2001; 56 (Suppl. 68): 128 (Abstr.).
23. Japanese Dermatological Association's definition and diagnosis of atopic dermatitis. Jpn J Dermatol 1994; 104: 176-7.
24. Hanifin JM, Rajka G. Diagnostic features of atopic eczema. Acta Derm Venereol (Stockh) 1980; 92; 44-7.
25. Loh Teck Hiong H. NSC therapeutic guidelines: treatment for atopic dermatitis. NSC Bull 2000; 11: 24.
26. Hannuksela M, Kalimo K, Lammintausta K et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy 1993; 70: 127-33.
27. Kawashima M, Harada S. Efficacy and safety of fexofenadine HCl in Japanese patients with chronic idiopathic urticaria. Int Arch Allergy Immunol 2001: 124; 343-5.
28. Kawashima M. Efficacy and safety of fexofenadine HCl at 60 mg for the treatment of pruritus cutaneous. Rinsho Iyaku 2002; 18: 319-34.
29. Kawashima M. Efficacy and safety of fexofenadine HCl for the treatment of eczema or dermatitis. Rinsho Iyaku 2002: 18: 297-317.
30. Simons FER, Silver NA, Gu X, Simons KJ. Skin concentrations of H1-receptor antagonists. J Allergy Clin Immunol 2001; 107: 526-30.